Navigation Links
Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Unilife Medical Solutions Limited
Date:1/7/2009

NEW YORK, Jan. 7 /PRNewswire/ -- Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview(R) (EIO(R)) on Unilife Medical Solutions Limited (UNI-ASX). The full 72-page report can be found at www.crystalra.com and www.unilife.com.

Unilife Medical Solutions Limited ("Unilife" or "the Company") develops and supplies innovative safety medical devices to healthcare and pharmaceutical markets. Specifically, the Company is focused on targeting pharmaceutical markets for prefilled safety syringes; healthcare markets that mandate the use of sharps safety devices to prevent needlestick injuries; and the U.S. medical device contract manufacturing market. Unilife has developed a patent-protected portfolio of safety syringes, with product lines including the Unilife Ready-to-Fill Syringe ([RTFS] hereafter referred to as the Unilife Prefilled Syringe), the Unitract(TM) 1mL Insulin and Safe Syringes, and the Unitract(TM) Clinical Range.

The key distinctive feature in all of Unilife's safety syringes is that the operator may control the speed of automatic needle retraction within a fully integrated safety syringe. This novel combination of safety features, which Unilife does not believe is available with any other technology on the market today, can virtually eliminate the risk of acquiring bloodborne infections, such as the human immunodeficiency virus (HIV) or hepatitis C, via needlestick injuries or aerosol (blood splatter).

In July 2008, sanofi-aventis SA (SNY-NYSE) -- the world's fourth largest pharmaceutical group and largest purchaser of prefilled syringes -- signed an Exclusive Agreement with Unilife, under which sanofi-aventis paid $13.9 million (euro 10 million) for the right to purchase the Unilife Prefilled Syringe for five years. Sanofi-aventis is also financing Unilife's three-year industrialization program for the Unilife Prefilled Syringe, which could have a total value of up to $23.6 million (euro 17 million). The Company believes that this alliance validates the strength of its proprietary technology and its competency in the development and operation of automated assembly systems. Upon the expected signing of two additional agreements with sanofi-aventis in the next 18 months, Unilife maintains a solid cash position and projects profitable operations moving forward.

About Crystal Research Associates, LLC

Crystal Research Associates, LLC is an independent research firm that provides institutional-quality, fee-based research to small and mid-cap companies. Crystal Research Associates' unique and novel product, the Executive Informational Overview(R) (EIO(R)), is free of investment ratings, target prices, and forward-looking financial models. The EIO(R) presents a crystal clear, detailed report on a company (public or private) in a manner that is easily understood by the Wall Street financial community. The EIO(R) details a company's product/technology/service offerings, market size(s), key intellectual property, leadership, growth strategy, competition, risks, financial statements, key events, and other such fundamental information. Crystal Research Associates has offices in New York City, Delray Beach, Montreal, and Toronto. Crystal Research Associates has been compensated by the Company in cash of forty-two thousand five hundred U.S. dollars and five hundred thousand Options/Warrants to purchase Unilife stock for its services in creating this report, for updates, and for printing costs.

Forward-Looking Safe Harbor Statement

Statements in this news release regarding future financial and operating results, potential applications of the Company's technology, opportunities for the Company, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements including, limited operating history, need for future capital, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in the Company's periodic reports, including forms filed with the Australian Securities Exchange (ASX).

These statements, and other forward-looking statements, are not guarantees of future performance and involve risks and uncertainties. Crystal Research Associates assumes no obligation to update any of the forward-looking statements in this release.


'/>"/>
SOURCE Crystal Research Associates, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Crystallography reveals the 3-D structure of mammalian sperm receptor
2. Asia Wellness Cruise Offers Crystal Guests Peace of Mind, Body & Spirit
3. Crystalens HD(TM) Receives FDA Approval
4. Success for Crystal Meth Drug Addict on YouTube
5. Steve and Paula Mae Schwartz Honored With Publicity Club of New Englands Crystal Bell Award
6. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on BioCurex, Inc.
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Advaxis, Inc.
8. Measurement technique probes surface structure of gold nanocrystals
9. Crystal Light and Mandy Moore Launch Unique Online Wellness Community for Women
10. Wellness Experts From Cleveland Clinic Set for 2008 Crystal Voyages
11. A New Year, A New Opportunity: Metropolitan Community Church Leaders Urge Faith Leaders to Address HIV and Crystal Meth Use Among LGBT Youth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... The ... the Rhode Island Consortium for Autism Research and Treatment (RI-CART) and Cinemaworld to ... autism spectrum disorder (ASD) to see films in an environment that accommodates their ...
(Date:2/23/2017)... ... February 23, 2017 , ... CALNOC, the nation’s first and only ... their upcoming conference – Empowerment, Value and Collaboration – in Seattle, WA on October ... the Virginia Mason Health System in Seattle since 2000. In addition to his role ...
(Date:2/23/2017)... New York (PRWEB) , ... February 23, 2017 , ... ... evaluate the safety and efficacy of CM-AT in children aged 3-8 with Autism, is ... 30 clinical sites already enrolling children across the United States. , “There are ...
(Date:2/23/2017)... ... February 23, 2017 , ... Thomas Vas-Don ... disciplined exercise regime, the author was able to successfully recover. In “ Origin & ... information for various sources on the principals of massage, anatomy , trigger ...
(Date:2/22/2017)... Setauket, New York (PRWEB) , ... February 22, ... ... main floor entrance and lobby of a new healthcare contact center in Georgia, ... results. , One of the nation’s largest healthcare systems recently invested $51 million ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... 2017 Research and Markets has announced the ... Industry Forecast to 2025" report to their offering. ... The Global Endoscopy Market ... the next decade to reach approximately $47.6 billion by 2025. ... for all the given segments on global as well as regional ...
(Date:2/23/2017)... 2017 Persistence Market Research ... market for intraoperative imaging, excerpts from which predict ... 513.9 million. According to the report, the demand ... grounds of increasing adoption of minimally-invasive surgeries and ... imaging for neurosurgeries. The world,s leading medical research ...
(Date:2/23/2017)... , February 23, 2017 On Wednesday, ... day as four out of nine sectors finished the trading ... managed a flat closing. Major US indices were also mixed ... the day at 5,860.63, slightly down by 0.09%; the Dow ... and the S&P 500 closed at 2,362.82, down 0.11%. This ...
Breaking Medicine Technology: